Regarding diabetes and biotics, studies of patients receiving TNF-α antagonists had a lower risk of new diabetes compared with those receiving other drugs, with an adjusted diabetes risk ratio of 0.62 (95%CI: 0.42–0.91) (Solomon et al., 2011). The gene discussed is TNF; the disease is diabetes mellitus.